International Conference and Exhibition on Gastrointestinal Therapeutics
Menoufia University, Egypt
Title: New era of hemostasis (Hemospray: A magic powder)
Biography: Ehab Abdelatty
Gastrointestinal (GI) bleeding is a common clinical problem and one of the most important emergencies in gastroenterology. UGIT bleeding may be due to general causes (Coagulation defects or Bleeding disorders) or local causes (Esophageal, Gastric lesions or duodenal lesions). Mortality rate is still high about 5%–10% in patients with peptic ulcer bleeding and about 15% in those with variceal hemorrhage. 5-10% of patients will not be initially controlled by endoscopic intervention or they will experience a recurrence of bleeding in the first 24 to 72 hours. Hemospray (TC-325) is a novel hemostatic agent for the treatment of uncontrolled gastrointestinal bleeding (Variceal hemorrhage, Peptic ulcer, colonic ulcer, bleeding malignant tumors). It is a hemostatic spray propelled by carbon dioxide under pressure, which can achieve rapid hemostasis 92-100% of the cases. The powder forms a barrier over the vessel wall, quickly stopping the bleeding and increases the local concentration and activating platelets and of clotting factors and enhances thrombus formation. It is not absorbed or metabolized by mucosal tissue (no risk of systemic toxicity). Hemostatic spray is safe, quick, simple and easy. It does not require very precise targeting such as deployment of hemoclips. It covers a large surface area as bleeding malignant tumors. The effects of the spray disappear within 24 h to 72 hour. It stops uncontrolled GIT bleeding in 93-100% of cases. Hemospray appears to allow safe control of acute bleeding and may be used in high-risk cases as a temporary measure or a bridge toward more definitive therapy.